Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Plexium, Inc.
Amgen, J&J, Takeda R&D Heads On The Era Of Human Data, Treating Disease Earlier
Big pharma R&D leaders discuss the confluence of technology and biotech driving insights into biology and how industry is doing in terms of identifying patients earlier in disease.
Deal Watch: Dragonfly Adds Gilead To Its List Of Big-Name Partners
AbbVie inks collaboration and option deal focused on targeted protein degradation with Plexium. Cend and Calabrius merge in an all-stock transaction.
Rough Guide To Targeted Protein Degradation
By hijacking a process that cells use to keep themselves shipshape, targeted protein degradation has become a hot new area of drug development. In Vivo takes an in-depth look at the field ahead of a wave of data expected this year from early candidates that will give some insight into whether this strategy will truly open a new way to combat disease.
Finance Watch: Platforms Are Great, But Investors Want To See Drug Candidates
Private Company Edition: Panelists at Biocom’s Global Life Science Partnering Conference noted a shift in the types of early-stage drug developers getting venture funding going forward. In recent financings, Synthego closed a $200m series E and Plexium raised $102m.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.